BACKGROUND: Although inflammatory markers may be associated with risk of cardiovascular events, few data are available regarding these markers and their association with left ventricular hypertrophy (LVH). We sought to evaluate whether inflammatory markers were independently associated with LVH in a multiethnic population in northern Manhattan. METHODS: A population-based cross-sectional study was conducted in 660 participants without stroke, who had undergone both transthoracic echocardiography and testing for soluble tumor necrosis factor receptor (sTNFR) 1, interleukin (IL)-6, and high-sensitivity C-reactive protein (hsCRP). LV mass was calculated according to an established formula. LVH was defined as LV mass >90th percentile of the participants. RESULTS: The mean age was 67.4 +/- 8.8 years, 35.5% were men, 61.7% were Hispanic, 19.7% were black, and 18.6% were white. In univariate analyses, hsCRP, IL-6, and sTNFR1 were significantly associated with LV mass. Multiple linear regression analyses demonstrated that sTNFR1 (P = 0.0008) was associated with LV mass after adjusting for demographic and medical risk factors, but hsCRP and IL-6 were not. When all markers were included in the same model, sTNFR1 remained significant, but hsCRP and IL-6 did not. Compared with the lowest quartile of sTNFR1, those in the highest quartile were more likely to have LVH (odds ratio = 1.84, 95% confidence interval, 0.97-3.64, P = 0.06). CONCLUSIONS: sTNFR1, but not hsCRP nor IL-6, is independently associated with increased LV mass. Chronic subclinical inflammation including the TNFR1-associated system may contribute to LVH.
BACKGROUND: Although inflammatory markers may be associated with risk of cardiovascular events, few data are available regarding these markers and their association with left ventricular hypertrophy (LVH). We sought to evaluate whether inflammatory markers were independently associated with LVH in a multiethnic population in northern Manhattan. METHODS: A population-based cross-sectional study was conducted in 660 participants without stroke, who had undergone both transthoracic echocardiography and testing for soluble tumor necrosis factor receptor (sTNFR) 1, interleukin (IL)-6, and high-sensitivity C-reactive protein (hsCRP). LV mass was calculated according to an established formula. LVH was defined as LV mass >90th percentile of the participants. RESULTS: The mean age was 67.4 +/- 8.8 years, 35.5% were men, 61.7% were Hispanic, 19.7% were black, and 18.6% were white. In univariate analyses, hsCRP, IL-6, and sTNFR1 were significantly associated with LV mass. Multiple linear regression analyses demonstrated that sTNFR1 (P = 0.0008) was associated with LV mass after adjusting for demographic and medical risk factors, but hsCRP and IL-6 were not. When all markers were included in the same model, sTNFR1 remained significant, but hsCRP and IL-6 did not. Compared with the lowest quartile of sTNFR1, those in the highest quartile were more likely to have LVH (odds ratio = 1.84, 95% confidence interval, 0.97-3.64, P = 0.06). CONCLUSIONS: sTNFR1, but not hsCRP nor IL-6, is independently associated with increased LV mass. Chronic subclinical inflammation including the TNFR1-associated system may contribute to LVH.
Authors: M Sano; K Fukuda; H Kodama; J Pan; M Saito; J Matsuzaki; T Takahashi; S Makino; T Kato; S Ogawa Journal: J Biol Chem Date: 2000-09-22 Impact factor: 5.157
Authors: M Rauchhaus; W Doehner; D P Francis; C Davos; M Kemp; C Liebenthal; J Niebauer; J Hooper; H D Volk; A J Coats; S D Anker Journal: Circulation Date: 2000-12-19 Impact factor: 29.690
Authors: Glenn M Chertow; Paolo Raggi; Scott Chasan-Taber; Juergen Bommer; Herwig Holzer; Steven K Burke Journal: Nephrol Dial Transplant Date: 2004-04-21 Impact factor: 5.992
Authors: Yoshihiro Higuchi; Charles F McTiernan; Carole B Frye; Brian S McGowan; Tung O Chan; Arthur M Feldman Journal: Circulation Date: 2004-03-29 Impact factor: 29.690
Authors: Stephan Gielen; Volker Adams; Sven Möbius-Winkler; Axel Linke; Sandra Erbs; Jiangtao Yu; Werner Kempf; Andreas Schubert; Gerhard Schuler; Rainer Hambrecht Journal: J Am Coll Cardiol Date: 2003-09-03 Impact factor: 24.094
Authors: Hannah Gardener; Tatjana Rundek; Clinton B Wright; Yian Gu; Nikolaos Scarmeas; Shunichi Homma; Cesare Russo; Mitchell S V Elkind; Ralph L Sacco; Marco R Di Tullio Journal: Am J Cardiol Date: 2014-11-29 Impact factor: 2.778
Authors: Jorge M Luna; Yeseon Moon; Khin Liu; Steven Spitalnik; Myunghee Paik; Ralph Sacco; Mitchell S V Elkind Journal: Age Ageing Date: 2013-01-15 Impact factor: 10.668
Authors: Julio R Vieira; Mitchell S V Elkind; Yeseon Park Moon; Tatjana Rundek; Bernadette Boden-Albala; Myunghee C Paik; Ralph L Sacco; Clinton B Wright Journal: Neuroepidemiology Date: 2011-10-15 Impact factor: 3.282
Authors: D Medenwald; S Dietz; D Tiller; A Kluttig; Kh Greiser; H Loppnow; J Thiery; S Nuding; M Russ; A Fahrig; J Haerting; K Werdan Journal: Open Heart Date: 2014-02-08
Authors: Luis M Beltrán; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Jesús Egido; Juan García-Puig; Juan Antonio Moreno Journal: Vasc Health Risk Manag Date: 2015-01-06
Authors: Eunjin Bae; Ran-Hui Cha; Yong C Kim; Jung N An; Dong K Kim; Kyung D Yoo; Su M Lee; Myoung-Hee Kim; Jung T Park; Shin-Wook Kang; Jae Y Park; Chun S Lim; Yon S Kim; Seung H Yang; Jung P Lee Journal: Medicine (Baltimore) Date: 2017-05 Impact factor: 1.889
Authors: Markus P Schneider; Johannes B Scheppach; Ulrike Raff; Sebastian Toncar; Christian Ritter; Thorsten Klink; Stefan Störk; Christoph Wanner; Georg Schlieper; Turgay Saritas; Sebastian D Reinartz; Jürgen Floege; Nele Friedrich; Rolf Janka; Michael Uder; Roland E Schmieder; Kai-Uwe Eckardt Journal: Kidney Int Rep Date: 2018-10-11